ILMN Illumina Inc.

KILL Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit

Illumina, Inc. requests that their press release NewsItemId: 20201112005379 “Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit” be removed.

EN
13/11/2020

Underlying

ILMNIllumina Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Illumina Inc.

ILMN ILLUMINA INC.

Illumina, Inc.: Update to credit analysis

Our credit view of this issuer reflects its modest financial leverage, offset by US policies around research funding and tariffs.

03/13/26 March 13, 2026 1 EN
ILMN ILLUMINA INC.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Illumina, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 6 March 2026 in which we reassessed the appropriateness of the ratings in the context of the...

03/12/26 March 12, 2026 1 EN
Free Trial
ILMN ILLUMINA INC.

Illumina Inc: 1 director

A director at Illumina Inc sold 2,370 shares at 116.180USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

02/19/26 February 19, 2026 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.50
ILMN ILLUMINA INC.
WAT Waters Corporat... ... (+28)

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

ILMN ILLUMINA INC.
WAT WATERS CORPORATION
VCYT VERACYTE INC
TMO THERMO FISHER SCIENTIFIC INC.
RGEN REPLIGEN CORPORATION
PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC.
IDXX IDEXX LABORATORIES INC.
HALO HALOZYME THERAPEUTICS INC.
EXEL EXELIXIS INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BRKR BRUKER CORPORATION
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ANGO ANGIODYNAMICS INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
IONS IONIS PHARMACEUTICALS INC.
PKI PERKINELMER INC.
UTHR UNITED THERAPEUTICS CORPORATION
FLGT FULGENT GENETICS
MDGL MADRIGAL PHARMACEUTICALS
CELC CELCUITY
DNLI DENALI THERAPEUTICS INC
STE STERIS PLC
CSTL CASTLE BIOSCIENCES
TXG 10X GENOMICS INC CLASS A
VIR VIR BIOTECHNOLOGY
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
PRPO PRECIPIO INC.
11/25/25 November 25, 2025 1 EN
EUR 152.98
ILMN ILLUMINA INC.

Moody's Ratings assigns Baa3 rating to Illumina's senior notes; outloo...

Moody's Ratings (Moody's) assigned a Baa3 rating to the senior unsecured notes offering of Illumina, Inc. (Illumina). There are no changes to Illumina's existing ratings including the Baa3 senior unsecured notes, Baa3 issuer rating and (P)Baa3 senior unsecured shelf registration. The outlook is unch...

11/10/25 November 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch